A recent New York Times article has been the talk of the human research protection community of late. The article describes how some participants in an investigational Alzheimer’s disease drug study were not told they had a genetic test result that may have indicated increased risks of the test article for them. The story raises numerous issues about adequate informed consent and transparency about risks in a population with a debilitating disease with limited treatment options.
Email paalediths@uams.edu at the IRB Blog Central Original Sources Department if you have trouble accessing the article.